European Society for Medical Oncology

To cite this living guideline, please include the original Clinical Practice Guideline citation
(Ann Oncol. 2025;36(5);491-506) and this online publication, including date and version number: "ESMO Living Guideline: Hepatocellular Carcinoma, v1.0 April 2025“

This living guideline was prepared by A Vogel, D Martins-Branco, G Pentheroudakis and M Ducreux, on behalf of the Clinical Practice Guideline author group.

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol 2021;32(12): 1475-1495" and this online publication, including date and version number: "ESMO Metastatic Breast Cancer Living Guideline, v1.2 April 2025“

This living guideline was initially prepared by G Curigliano, L Castelo-Branco, A Gennari, N Harbeck, C Criscitiello and D Trapani, on behalf of the Clinical Practice Guideline author group.

v1.2 was prepared by A Gennari, D Martins-Branco, D Trapani, G Pentheroudakis, G Curigliano and N Harbeck.

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol. 2025;36(1):10-30" and this online publication, including date and version number: "ESMO Living Guideline: Cutaneous Melanoma, v1.0 February 2025“
 
This living guideline was prepared by T Amaral, M Ottaviano, D Martins Branco, G Pentheroudakis and P A Ascierto, on behalf of the Clinical Practice Guideline author group.

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol. 2023;34(4):358-376" and this online publication, including date and version number: "ESMO Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guideline, v1.2 January 2025"

This living guideline was prepared by L Hendriks, F Cortiula, E Mariamidze, L Castelo-Branco, D Martins-Branco, C Sessa, G Pentheroudakis and M Reck, on behalf of the Clinical Practice Guideline author group.

v1.2 was prepared by L Hendriks, F Cortiula, E Mariamidze, D Martins-Branco, M Reck and S Popat, and has been peer reviewed.

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol. 2023;34(4):339-357" and this online publication, including date and version number: "ESMO Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guideline, v1.2 January 2025“

This living guideline was prepared by L Hendriks, F Cortiula, E Mariamidze, D Martins-Branco, G Pentheroudakis and M Reck, on behalf of the Clinical Practice Guideline author group.

v1.2 was prepared by L Hendriks, F Cortiula, E Mariamidze, D Martins-Branco, M Reck and S. Popat, and has been peer reviewed.

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol 2022;33(10):1005-1020" and this online publication, including date and version number: "ESMO Gastric Cancer Living Guideline, v1.4 September 2024"

This living guideline was initially prepared by F Lordick, L Candia Montero, L Castelo-Branco, G Pentheroudakis, C Sessa and E Smyth, on behalf of the Clinical Practice Guideline author group.
v1.4 was prepared by F Lordick and E Smyth.

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol 2023;34(1):10-32" and this online publication, including date and version number:"ESMO Metastatic Colorectal Cancer Living Guideline, v1.2 September 2024"

This living guideline was prepared by A Cervantes, L Castelo-Branco, L Candia Montero, C Sessa, G Pentheroudakis and E Martinelli, on behalf of the Clinical Practice Guideline author group.
v1.2 was prepared by A Cervantes, L Candia Montero, G Pentheroudakis and E Martinelli.
Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living Guideline ("Ann Oncol 2025;36(3):342-344")